%0 Journal Article
%A Gkika, Eleni
%A Firat, Elke
%A Adebahr, Sonja
%A Graf, Erika
%A Popp, Ilinca
%A Eichhorst, Alexandra
%A Radicioni, Gianluca
%A Lo, Simon S
%A Spohn, Simon K B
%A Nestle, Ursula
%A Nicolay, Nils H
%A Niedermann, Gabriele
%A Grosu, Anca-L
%A Duda, Dan G
%T A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.
%J Radiotherapy and oncology
%V 207
%@ 0167-8140
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2025-00770
%P 110889
%D 2025
%Z Volume 207, June 2025, 110889
%X We evaluated the longitudinal effects of stereotactic body radiotherapy (SBRT) on circulating immune cells.Patients with oligometastatic/oligoprogressive pulmonary lesions were treated with ablative SBRT with (cSBRT) or without (SBRT group) concurrent systemic treatment (chemotherapy or immune checkpoint blockade, ICB) using different fractionation regimes. Immunoprofiling of peripheral blood cells was performed at baseline, during, and at the end of SBRT, and during the first (FU1) and second follow-ups (FU2). The primary endpoint was the increase in CD8+ T cells at FU1 compared to baseline.The study accrued 100 patients, 80 with evaluable samples. At FU1 12 
%K Immune modulation (Other)
%K Immunomodulatory effects (Other)
%K Lung cancer (Other)
%K Lung metastases (Other)
%K SBRT (Other)
%K Stereotactic body radiotherapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40209858
%R 10.1016/j.radonc.2025.110889
%U https://inrepo02.dkfz.de/record/300324